SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Public ClinicalTrials.gov record NCT00076349. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-Center Phase II Study to Investigate the Safety and Activity of SDX-105 (Bendamustine) in Combination With Rituximab in Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
SUMMARY: This is an open label study combining Rituxan and SDX-105. Rituxan will be given on day 1 followed by a 30-60 minute intravenous infusion of SDX-105 on day 2 and day 3. Treatment will repeat every 21 days (a cycle). Treatment can continue for up to 6 cycles (about 4 months) if tumor status improves and there are no unacceptable side effects. Patients will be followed for up to 2 years or until disease progression. RATIONALE: Rituxan has been shown to increase the sensitivity of cells to chemotherapy. The combination of SDX-105 and Rituxan has been effective in both the laboratory and in a recent clinical study with Non-Hodgkin's lymphoma patients. PURPOSE: This study will evaluate the safety and effectiveness of SDX-105 plus Rituxan in patients with Non-Hodgkin's lymphoma who have relapsed after taking Rituxan.
Study identification
- NCT ID
- NCT00076349
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 66 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2004 (Type not available)
- Primary completion
- Dec 2005 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- May 9, 2014
2004 – 2008
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Cancer Research and Education Center | Anchorage | Alaska | 99508 | — |
| Bay Area Cancer Research Group | Concord | California | 94520 | — |
| Wilshire Oncology Medical Group | La Verne | California | 91750 | — |
| USC/Kenneth Norris Jr. Cancer Hospital and Research Institute | Los Angeles | California | 90033 | — |
| San Diego Cancer Center | Vista | California | 92081 | — |
| Hematology Oncology, P.C. Carl and Dorothy Bennett Cancer Center | Stamford | Connecticut | 06902-3628 | — |
| Georgetown University Medical Center - Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Pasco Hernando Oncology | New Port Richey | Florida | 34652 | — |
| John B. Amos Cancer Center | Columbus | Georgia | 31902 | — |
| Suburban Hematology & Oncology Associates | Lawrenceville | Georgia | 30045 | — |
| Georgia Oncology Partners Research and Education Foundation | Macon | Georgia | 31201 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Oncology and Hematology | Metairie | Louisiana | 70006-2921 | — |
| LSU Health Sciences Center | Shreveport | Louisiana | 71103 | — |
| Beth Israel/Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Hubert H. Humphrey Cancer Center | Robbinsdale | Minnesota | 55422 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | — |
| Arena Oncology Associates | Great Neck | New York | 11021 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | — |
| Upstate NY Cancer Research & Education Foundation, Inc. - Interlakes Oncology/Hematology | Rochester | New York | 14623 | — |
| ACORN - West Cancer Center | Memphis | Tennessee | 38120 | — |
| Southwest Regional Cancer Center | Austin | Texas | 78705 | — |
| Baylor University Medical Center | Dallas | Texas | 75246 | — |
| Univ. of Virginia Health System-Cancer Center Clinical Trials Office | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00076349, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 9, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00076349 live on ClinicalTrials.gov.